Owlstone Medical, a UK-based company specializing in Breath Biopsy® for early disease detection, secured $6.5 million in funding. The funding includes a $5 million equity investment and a $1.5 million grant from the Bill & Melinda Gates Foundation. This marks the foundation's first equity position in a breath diagnostics company. The funding will support the development of breath-based diagnostic solutions for tuberculosis (TB) and HIV, with a focus on improving outcomes in the developing world. Owlstone aims to identify VOC biomarkers for TB and HIV detection, expanding their Breath Biopsy VOC Atlas database. Led by CEO Billy Boyle, Owlstone is dedicated to transforming infectious disease diagnosis through innovative technology.